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INTRODUCTION
J P E T # 1 9 3 5 8 1 5 their functional roles for being used as immediate response elements (Stetler et al., 2009 ). Hsp27, a member of the small-Hsp family, acts as an endogenous cytoprotective stress response protein, eliciting cardioprotection to ischemic injury, via its role as a molecular chaperone and in phosphorylation-dependent stabilization of actin (Peart et al., 2007) . Hsp27 can be reversibly phosphorylated on three serine residues by the mitogen-activated protein kinases 2 and 3 (MK2/3), which are themselves activated by phosphorylation through either the p38 or the extracellular signal-regulated protein kinase (ERK) signalling pathway (Jantschitsch et al., 1988; Guay et al., 1997; Morrow and Tanway, 2003; Duverger et al., 2004; O'shaughnessy et al., 2007) . ERK transduces a broad range of extracellular stimuli to yield diverse intracellular responses. The ERK signalling pathway could be important as a regulator of cardiac function (Michel et al., 2001 ) and may play an important role in the coupling of CRF neuron excitation with both gene induction as well as neurohormone secretion (Osterlund et al., 2011) . In addition, it has been shown that Hsp27 and Hsp70 are upregulated by ACTH (Blake et al., 1991; 1993) . However, the possible interaction between HPA axis/ERK and the activation of Hsp27 during morphine dependence and withdrawal has not been established.
It is known that drugs of abuse induce cardiac morphological alterations and cardiac disorders (Cerretani et al., 2008; Dettmeyer et al., 2009 ) but the mechanism underlying the drug-induced myocardial damages still remains unclear. Therefore, the purpose of the present study was to establish some mechanisms implicated in the cardiac adaptive changes observed during morphine withdrawal, here we examined 1) the expression of catecol-O-metyltransferase (COMT), normetanephrine (NMN) [extraneuronal noradrenaline (NA) metabolite generated by COMT], and NMN/NA ratio, as index of NA turnover, in morphine dependent and withdrawn rats; 2) the interaction between HPA axis and ERK pathways, investigating the effects of SL327, a selective
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J P E T # 1 9 3 5 8 1 6 inhibitor of ERK activation (Atkins et al., 1998) , on the plasma concentrations of ACTH and corticosterone; 3) the expression and phosphorylation of Hsp27 in serine 82 (Ser82) in order to determine the magnitude and severity of cellular stress during chronic morphine treatment and withdrawal; and 4) the activation of Hsp27 induced by morphine withdrawal in morphine dependent rats treated with SL327 or propranolol (a beta-adrenoceptor antagonist).
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MATERIALS AND METHODS

Animals and treatments
Male Sprague-Dawley rats (220-240 g at the beginning of the experiments) were housed four-to-five per cage under a 12-h light/dark cycle (light: 8:00-20:00 h) in a room with controlled temperature (22 ± 2ºC), humidity (50 ± 10%), food and water available ad libitum and prehandled for several days preceding the experiment to minimize stress, as previously described (Laorden et al., 2000) . All surgical and experimental procedures were performed according to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996) and approved by the local Committee.
Experimental procedure
Rats were rendered dependent on morphine by s.c. implantation of morphine base pellets (75 mg), one on day 1, two on day 3 and three on day 5, under light ether anaesthesia.
Control animals were implanted with placebo pellets containing lactose instead of morphine, on the same time schedule. These procedures have repeatedly been shown to induce both tolerance and dependence as measured behaviourally and biochemically (Rabadán et al., 1997) . On day 8, the animals pretreated with morphine or placebo pellets were injected with saline s.c. (control group) or naloxone (2 mg/kg s.c.) and decapitated 30, 60 and 90 min after the opioid antagonist administration. Another group of rats was injected with propranolol (3 mg/kg i.p) 20 min before naloxone administration. The chest was opened with a midsternal incision and the left ventricle was dissected and stored immediately at -80ºC, so this study was performed in the left ventricle.
Rats weight gain was checked during the treatment to ensure that morphine was liberated correctly from the pellets because it is known that chronic morphine treatment induces a decrease in body weight gain due to lower caloric intake (Berhow et al., 1995) . In addition,
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we determined the body weight before and after saline or naloxone injection to control and morphine dependent rats.
To determine the effect of inhibiting ERK phosphorylation on the morphine withdrawalinduced changes in HPA activation and in Hsp27 phosphorylation, Hsp27 phosphorylated at Ser82 immunoreactivity was determined by western-blot and plasma ACTH and corticosterone levels were determined by radioimmunoassay (RIA) in morphine dependent and control rats treated with SL327, a selective inhibitor of mitogen-activated extracellular protein kinase (MEK) (Atkins et al., 1998) or vehicle (DMSO), administered 1h before the injection of naloxone or saline. SL327 was dissolved in DMSO 100% and injected intraperitoneally at an injection volume of 1 ml/kg and at doses of 100 mg/kg.
Previous studies (Almela et al., 2008; 2009) have demonstrated that this dose of SL327 induces inhibition of ERK phosphorylation.
Radioimmunoassasy
Plasma ACTH and corticosterone concentrations were measured by commercially available kits for rats (  125 I-ACTH and   125 I-corticosterone radioimmunoassay; MP Biomedicals, Solon, OH). The sensitivity of the assay was 5.7 pg/ml for ACTH and 7.7 ng/ml for corticosterone.
Determination of NA and its metabolite NMN in the left ventricle
NA and its metabolite NMN were determined by high-performance liquid chromatography (HPLC) with electrochemical detection. Each tissue was weighed, placed in a dry-cooled propylene vial and homogenized with a Polytron-Type homogenizer in 1.5 ml perchloric acid (0.1 M). The homogenates were then centrifuged (8000 g, 4ºC, 15 min), the supernatant layer was removed into a 1-ml syringe and filtered through a 0.45 μm filter (Millipore, Bedford, USA) and centrifuged (6000 g, 4ºC, 20 min) again through Ultra free MC 0.2 filter (Millipore). From each sample, 10 μl was injected into a 5-μm C 18 reverse phase column This article has not been copyedited and formatted. The final version may differ from this version.
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(Waters, Milford, MA, USA) through a Rheodyne syringe-loading injector 200 μl loop.
Electrochemical detection was accomplished with a glass carbon electrode set at a potential of +0.65 V with respect to the Ag/AgCl reference electrode (Waters). The mobile phase consisted of a 95% (v/v) mixture of water and methanol with sodium acetate (50 mM), citric acid (20 mM), L-octyl-sodium sulfonate (3.75 mM), di-n-butylamine (1 mM) and EDTA (0.135 mM), adjusted to pH 4.3. The flow rate was 0.9 ml/min, and chromatographic data were analysed with Millenium 2010 Chromatography Manager Equipment (Millipore). NA and NMN were simultaneously detected by the described HPLC method at an elution time of 4.25 and 7.32 min, respectively. NA and NMN were quantified by reference to calibration curves run at the beginning and at the end of each series of assays. Linear relationships were observed between the amount of standard injected and the peak height measured.
The lower detection limit for both NA and NMN was 100 pg. The content of NA and NMN in the left ventricle was expressed as nanogram per gram of tissue weight.
Western blot analysis
Western blot analysis was performed for total Hsp27, Hsp27 phosphorylation, phosphorylated ERKs and COMT protein determination. Samples were placed in homogenization buffer [phosphate buffered saline, 2 % sodium dodecylsulfate (SDS) plus protease inhibitors (Roche, Germany) and phosphatase inhibitors Cocktail Set (Calbiochem, Germany)] and homogenized for 50 s prior to centrifugation at 6000 g for 20 min at 4ºC. Total protein concentrations were determined spectrophotometrically using the bicinchoninic acid method (Wiechelman et al., 1988 . Naloxone HCl was dissolved in sterile 0.9 % NaCl (saline) and administered in volumes of 0.1 mL/100g body weight.
Data analysis
Data are expressed as mean±SEM and analyzed using two-way or one-way (when required) ANOVA followed by a post hoc Newman Keuls test. Student's t-test was used when comparison were restricted to two experimental group. Differences with a p-value < 0.05 were considered significant. Figure 1 A,B,C, there was a significant enhancement in body weight loss after naloxone injection to morphine dependent rats, compared with control animals also receiving naloxone and with morphine dependent rats given saline. Acute naloxone injection had no effect in animals chronically treated with placebo, compared with the corresponding control group receiving saline.
In animals pretreated with propranolol or SL327, one-way ANOVA revealed significant differences in body weight loss (F 5,38 =23.21, p<0.0001). As shown in Figure 1D , naloxone injection to rats acutely treated with SL327 or propranolol induced a significant (p<0.001, one-way ANOVA) weight loss, similar to that described in the group chronically pretreated with vehicle plus morphine.
NA turnover in the left ventricle
Two-way ANOVA for NA showed a significant effect of naloxone injection (F 1,20 =11.96, whereas the increase of MB-COMT expression after morphine withdrawal was only significant (p<0.05) versus rats dependent on morphine and injected with saline.
ERK1/2 activation after chronic morphine treatment and withdrawal
The influence of morphine dependence and withdrawal on phosphorylated ERK1/2 was examined in the left ventricle 60 min after s.c. injection of saline or naloxone to control treatment had no effect on animals chronically treated with placebo. However, rats dependent on morphine and given naloxone showed a significant (p<0.01) elevation of phospho-ERK1 and phospho-ERK2 60 min after the administration of the opioid antagonist versus the control group injected with naloxone or the dependent group injected with saline.
According to previous studies from our laboratory (Almela 2008 (Almela , 2009 demonstrating that SL327 (100 mg/kg, i.p.) reduced basal expression of phospho-ERK1/2 immunoreactivity in the heart, rats were pretreated with SL327 (100 mg/kg, i.p.). As shown in Figure 3 C,D, phosphorylation of ERK1/2 was significantly (p<0.001) decreased in the presence of SL327 in both controls and morphine withdrawn animals.
Influence of morphine withdrawal on HPA axis activation
One-way ANOVA revealed significant differences in plasma ACTH levels (F 5,18 =8.330, p=0.0003) and plasma corticosterone levels (F 5,18 =24.72, p<0.0001) in rats pretreated with vehicle, propranolol or SL327. As shown in Figure 4 A,B, naloxone-precipitated morphine withdrawal evoked a dramatic increase (p<0.001) of both corticosterone and ACTH secretion compared with morphine dependent rats treated with saline instead of naloxone or placebo rats injected with the opioid antagonist.
To evaluate the role for NA in the regulation of CRF release and pituitary-adrenal function we have evaluated the effects of propranolol (3 mg/kg, i.p.) on plasma ACTH and corticosterone concentrations. As it can be seen in Figure 4A , administration of propranolol 20 min before naloxone to morphine dependent rats significantly (P<0.05) decreased plasma ACTH concentrations compared with the group treated with vehicle instead of propranolol. However, the beta-adrenoceptor antagonist did not prevent the enhancement of corticosterone secretion observed after naloxone-induced withdrawal in morphine dependent rats ( Figure 4B ). Since previous studies (Nuñez et al., 2007 (Nuñez et al., , 2009 ) from our laboratory have demonstrated an enhancement of ERK 1/2 after naloxone precipitated withdrawal in the PVN in the present study we have investigated if a causal link exists between ERK1/2 and HPA axis activation during morphine withdrawal. We measured plasma ACTH and corticosterone concentrations in animals made dependent on morphine and treated with SL327 (100 mg/kg, i.p.) 60 min before naloxone administration. SL327 significantly (p<0.01) reduced morphine withdrawal-induced increases in plasma ACTH compared with rats receiving vehicle instead of SL327 whereas plasma ACTH in morphine dependent rats injected with SL327+naloxone was significantly (p<0.05) higher than in morphine+vehicle+saline or placebo+SL327+naloxone groups. Similarly to propranolol SL327 did not modify the increase of corticosterone levels observed during morphine withdrawal (Figure 4 A,B)
Expression of Hsp27 and phospho-Hsp27 in chronic morphine treatment and withdrawal
We examined Hsp27 expression and phospho-Hsp27 at Ser 82, which is highly expressed in the heart (Kato et al., 1992) to determine the magnitude and severity of cellular stress during chronic morphine treatment and withdrawal. (Figure 5 A,B,C) . Acute naloxone treatment had no effect on animals chronically treated with placebo (control). However, Hsp27 expression was increased (p<0.05) 30, 60 and 90 min after naloxone injection to rats dependent on morphine versus the control group chronically treated with placebo and injected with naloxone ( Figure 5 A,B,C).
This article has not been copyedited and formatted. The final version may differ from this version. Figure 6 A,B,C, after saline injection to morphine dependent rats, there were not changes in the levels of phospho-Ser82-Hsp27. However, rats dependent on morphine and given naloxone showed significant (p<0.01) increases in phospho-Ser82-Hsp27 after the opioid antagonist injection compared with the corresponding placebo group receiving naloxone and with the morphine dependent animals receiving saline (30 min: p<0.01; 60 min: p<0.01; 90 min: p<0.05) (Figure 6 A,B,C). The ratio phospho-Hsp27/total-Hsp27 is represented in Figure 7 . Two-way ANOVA results for pHsp27/Hsp27 ratio revealed a We have evaluated the expression of Hsp27 and its phosphorylation at Ser82 in rats treated with propranolol, or SL327. Two-way ANOVA for Hsp27 in rats pretreated with propranolol revealed a main effect of morphine treatment (F 1,18 =11.77, p=0.0030). As observed in Figure 8 A that the pretreatment with SL327 did not modify the increase of Hsp27 expression observed after naloxone administration to morphine dependent rats ( Figure 8C ). In contrast, the administration of SL327 before naloxone significantly (p<0.001) reduced the activation (phosphorylation at Ser82) of Hsp27 in morphine withdrawn rats ( Figure 8D ). , 1982) . Since previous studies from our laboratory (Laorden et al., 2000) have demonstrated that the hyperactivity of the HPA axis during morphine withdrawal is mediated via a stimulatory noradrenergic pathway, we have investigated the role of beta-adrenoceptor in the HPA axis hyperactivity after morphine withdrawal. We found that propranolol significantly reduces the ability of morphine withdrawal to release ACTH, but this drug was not capable of modifying corticosterone secretion. We also measured plasma corticosterone and ACTH concentrations in animals made dependent on morphine and pretreated with SL327 to evaluate whether a causal link exists between ERK activation and HPA axis hyperactivation during morphine withdrawal. Similarly, to propranolol, SL327 did not block corticosterone release that is produced as a consequence of morphine withdrawal.
However, ACTH concentrations were found to be decreased in animals preteated with
SL327. Although the presence of pituitary ACTH is clearly essential for adrenocortical
This article has not been copyedited and formatted. The final version may differ from this version. Since the repeated exposure to morphine and its withdrawal induces profound and severe stress reactions that are also evidenced by overexpression of (Almela et al., 2011; Houshyar et al., 2001a Houshyar et al., , 2001b Sharma, 2004; Sharma et al., 2004 Hsp27) we have evaluated Hsp27 expression and activation in the left ventricle. According to previous data (Almela et al., 2011) , present investigation shows that chronic morphine treatment and its withdrawal are associated with an increase of Hsp27 expression. However, chronic Present data demonstrated an increase in phospho-ERK1 and phospho-ERK2 with a parallel increase in phospho-Hsp27 within the heart of rats withdrawn from morphine. . We found that treatment with SL327 decreases the activation of both Hsp27 and HPA axis suggesting that ERK activation triggers Hsp27 phosphorylation at Ser82 and ACTH plasma concentrations. Lastly, we examined if beta-adrenoceptors are involved in mediating the influence of noradrenergic pathways after naloxone-induced withdrawal. We found that propranolol reduces Hsp27 phosphorylation after naloxone-induced withdrawal suggesting that beta-adrenergic blockade in the heart attenuated the protective response to cellular stressors. According to these data, it is known that the administration of the beta-adrenoreceptor blocker, alprenolol during the triggering preconditioning phase of ischemia significantly attenuated cardioprotection (Lochner et al., 1999) . Since Hsp27 plays a pivotal role in the protection of the cell, the fact that propranolol decreases Hsp27 phosphorylation during morphine withdrawal below the control value, suggests that during stress situations beta-adrenoreceptor blockers abolish the endogenous protective mechanism that the heart has at its disposal in basal conditions. Because propranolol decreases ACTH and morphine withdrawal increases circulating levels of NA (Peart et al., 2007) and NA turnover in the heart, it is possible that changes in peripheral catecholamines represent an important mechanism in the stimulatory effect of naloxoneinduced withdrawal on the HPA axis. Together, these results demonstrated a reduction on plasma ACTH concentrations in parallel with a decrease in Hsp27 activation suggesting that Hsp27 phosphorylation at Ser82 is upregulated by ACTH. According to these results, it has been demonstrated in the adrenal cortex that stress induces an increased expression of Hsp70 (Blake et al., 1993; Udelsman et al., 1994) which was abolished in hypophysectomized rats (Blake et al., 1991; 1993) , suggesting a role for ACTH in that reduction. In adrenocortical tumors which secrete high quantities of cortisol (and thus lead to a reduction of ACTH production), it has been observed a depleted expression of Hsp27 and Hsp70 (Pignatelli et al., 2003) .
In conclusion, we present novel information regarding the ability of NA and ERK pathways to induce Hsp27 phosphorylation at Ser82 in the left ventricle, as well as the role that these pathways play in mediating HPA axis hyperactivity. The existence of a possible link between ACTH and Hsp27 remains to be determined. Nevertheless, we consider that these findings are important for our overall understanding of the mechanisms mediating morphine withdrawal, and also for the development of potential therapies designed to address the adverse consequences of the withdrawal.
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